Inovio Pharmaceuticals(US:INO) TMX Newsfile·2026-03-27 13:34Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. regarding alleged violations of federal securities laws related to misleading statements about the company's product development and regulatory prospects [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Inovio to contact them to discuss legal options, particularly for those who purchased securities between October 10, 2023, and December 26, 2025 [1]. - There is an April 7, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action against Inovio [2]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 for standard review but noted that the company did not provide sufficient information for accelerated approval [6]. - Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share following the FDA's announcement [7]. - Inovio plans to request a meeting with the FDA to discuss potential pathways for pursuing accelerated approval despite the current setback [6].